Evidence map›Paper›PMID 30087699›Full record

ArticleJournal of Cancer2018

Subtyping Of Triple Negative Breast Carcinoma On The Basis Of RTK Expression.

Harald Hessel, Manuela Poignée-Heger, Sabine Lohmann, Bianca Hirscher, Andrea Herold, Gerald Assmann, Jan Budczies, Karl Sotlar, Thomas Kirchner

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Harald HesselInstitute of Pathology, Faculty of Medicine, LMU Munich, Germany.
Manuela Poignée-HegerRoche Diagnostics GmbH, Penzberg, Germany.
Sabine LohmannRoche Diagnostics GmbH, Penzberg, Germany.
Bianca HirscherRoche Diagnostics International AG, Rotkreuz, Switzerland.
Andrea HeroldRoche Diagnostics GmbH, Penzberg, Germany.
Gerald AssmannInstitute of Pathology, Faculty of Medicine, LMU Munich, Germany.
Jan BudcziesInstitute of Pathology, Charité University Hospital, Berlin, Germany.
Karl SotlarInstitute of Pathology, Faculty of Medicine, LMU Munich, Germany.
Thomas KirchnerInstitute of Pathology, Faculty of Medicine, LMU Munich, Germany.
Roche Pharma AG (Germany) · DELMU Klinikum · DELudwig-Maximilians-Universität München · DECharité - Universitätsmedizin Berlin · DERoche (Switzerland) · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

personalized tumor therapyReal-Time RT-PCRreceptor tyrosine kinase (RTK)RTK-high gene signatureRTK-low gene signaturesubtypingtriple-negative breast cancer

Identifiers

PMID30087699
PMCPMC6072816
OpenAlexW2868320920

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.